No abstract available.
Carcinoma, Squamous Cell ; Drug Therapy ; Head

Animals ; Calcium Sulfate ; Osteogenesis ; Periosteum ; Rats ; Skull

No abstract available.
Lipomatosis*

The pleomorphic adenoma is the most common neoplasm involving both the major and minor salivary glands. It is a benign, slowgrowing tumor, but local recurrences can occur. The pleomorphic adenoma gene 1 (PLAG1), which is a novel zinc finger gene, is frequently activated by reciprocal chromosomal translocations involving 8q12 in a subset of salivary gland pleomorphic adenomas. This experimental study was preformed to observe the translocation patterns between PLAG1 gene and the three translocation partner genes. We also have analyzed the presence of PLAG1 transcripts by RT-PCR. CTNNB1/PLAG1 gene fusion was observed in three of nine pleomorphic adnomas. However, LIFR/PLAG1 and SII/PLAG1 gene fusions were not detectable. All of three gene fusions was not detectable in one Warthin's tumor and three inflammatory salivary gland tissues. PLAG1 transcripts were expressed in all inflammatory salivary gland tissues and tumors except for three pleomorphic adenomas. Of particular one pleomorphic adenoma showing CTNNB1/P AG1 gene fusion did not express PLAG1 transcipt. Our data indicate that gene fusion involving PLAG1 is a frequent event in pleomorphic adenoma, but correlation between gene fusion involving PLAG1 and PLAG1 transcription is not definite.
Adenoma, Pleomorphic* ; Gene Fusion ; Recurrence ; Salivary Glands* ; Salivary Glands, Minor ; Translocation, Genetic ; Zinc Fingers

Carcinoembryonic antigen (CEA) levels were measured in the serum of 35 normal control group and 200 urologic cases of tumor and non-tumor groups at the Department of Urology, National Medical Center during the period from November, 1981 to June, 1983. The following results were obtained: 1. Mean serum CEA level in normal control subjects was 3.2 +/- 2.4 ng/ml. 2. Incidence of positive results and mean serum CEA levels in each groups of disease were as follows: 15 of 30 cases (50%) and 30.0 ng/ml in tumor group, 9 of 30 cases (30.0%) and 9.6 ng/ml in benign prostatic hyperplasia, 13 of 55 cases (23.6%) and 7.4 ng/ml in calculous disease group, 5 of 30 cases (16.7%) and 12.8 ng/ml in infectious disease group, 3 of 26 cases ( 11.5%) and 4.6 ng/ml in congenital anomaly group, I of 14 cases (7.1%) and 4.1 ng/ml in injury group. 3. Incidence of positive results and mean serum CEA levels in each tumor were as follows: 9 of 14 cases (64.3%) and 44.6 ng/ml in bladder tumor, 3 of 3 cases (100%) and 33.7 ng/ml in prostate cancer, 1 of 4 cases (25%) and 8.0 ng/ml in renal cell carcinoma, 1 of 2 cases and 13.0 ng/ml in testis tumor, 1 of 1 case and 84.0 ng/ml in renal pelvis tumor. 4. Mostly the frequency of abnormal serum CEA values correlated with the grade and stage of bladder tumor. 5. The raised serum CEA levels declined to normal early in the postoperative period in the tumor and non-tumor groups if adequate surgery had been effected. 6. Due to low positive result in tumor group (50%) and relatively high positive results in non-tumor groups (20.5%), serum CEA values were of little value in the diagnosis of genitourinary tract tumor.
Carcinoembryonic Antigen ; Carcinoma, Renal Cell ; Communicable Diseases ; Diagnosis ; Incidence ; Kidney Pelvis ; Postoperative Period ; Prostatic Hyperplasia ; Prostatic Neoplasms ; Testis ; Urinary Bladder Neoplasms ; Urologic Diseases* ; Urology

Carcinoembryonic antigen (CEA) levels were measured in the serum of 35 normal control group and 200 urologic cases of tumor and non-tumor groups at the Department of Urology, National Medical Center during the period from November, 1981 to June, 1983. The following results were obtained: 1. Mean serum CEA level in normal control subjects was 3.2 +/- 2.4 ng/ml. 2. Incidence of positive results and mean serum CEA levels in each groups of disease were as follows: 15 of 30 cases (50%) and 30.0 ng/ml in tumor group, 9 of 30 cases (30.0%) and 9.6 ng/ml in benign prostatic hyperplasia, 13 of 55 cases (23.6%) and 7.4 ng/ml in calculous disease group, 5 of 30 cases (16.7%) and 12.8 ng/ml in infectious disease group, 3 of 26 cases ( 11.5%) and 4.6 ng/ml in congenital anomaly group, I of 14 cases (7.1%) and 4.1 ng/ml in injury group. 3. Incidence of positive results and mean serum CEA levels in each tumor were as follows: 9 of 14 cases (64.3%) and 44.6 ng/ml in bladder tumor, 3 of 3 cases (100%) and 33.7 ng/ml in prostate cancer, 1 of 4 cases (25%) and 8.0 ng/ml in renal cell carcinoma, 1 of 2 cases and 13.0 ng/ml in testis tumor, 1 of 1 case and 84.0 ng/ml in renal pelvis tumor. 4. Mostly the frequency of abnormal serum CEA values correlated with the grade and stage of bladder tumor. 5. The raised serum CEA levels declined to normal early in the postoperative period in the tumor and non-tumor groups if adequate surgery had been effected. 6. Due to low positive result in tumor group (50%) and relatively high positive results in non-tumor groups (20.5%), serum CEA values were of little value in the diagnosis of genitourinary tract tumor.
Carcinoembryonic Antigen ; Carcinoma, Renal Cell ; Communicable Diseases ; Diagnosis ; Incidence ; Kidney Pelvis ; Postoperative Period ; Prostatic Hyperplasia ; Prostatic Neoplasms ; Testis ; Urinary Bladder Neoplasms ; Urologic Diseases* ; Urology

No abstract available.
Hyperplasia

Anesthesia ; Anesthesia, Local ; Animals ; Constriction ; Epinephrine ; Hemostasis ; Lidocaine ; Mandibular Nerve ; Rats ; Tongue

No abstract available.
Meningioma* ; Paragonimiasis*

No abstract available.
Hand*